Xenetic Biosciences Retained Earnings Over Time
| XBIO Stock | USD 4.11 0.10 2.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xenetic Biosciences Performance and Xenetic Biosciences Correlation. Xenetic |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Retained Earnings Analysis
Compare Xenetic Biosciences and related stocks such as Transcode Therapeutics, Landos Biopharma, and Neximmune Retained Earnings Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RNAZ | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (510.8 K) | (1.1 M) | (3.5 M) | (10.3 M) | (27.9 M) | (46.4 M) | (44.1 M) |
| ZVSA | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (52.9 M) | (4.9 M) | (103.2 M) | (98.1 M) |
| IMMX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (5.4 M) | (29.8 M) | (38 M) | (53.4 M) | (50.7 M) |
| PHIO | (4.3 M) | (4.3 M) | (17.2 M) | (38.1 M) | (46.9 M) | (57.1 M) | (66.1 M) | (78.6 M) | (85.9 M) | (94.8 M) | (103.6 M) | (116.9 M) | (128.4 M) | (139.2 M) | (132.2 M) |
| ATNF | (3.1 K) | (3.1 K) | (3.1 K) | (3.1 K) | (3.1 K) | (3.1 K) | (3.1 K) | 120.7 K | 1.2 M | (37.5 M) | (48.4 M) | (68.7 M) | (107.4 M) | (127.3 M) | (121 M) |
| REVB | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 35.1 M | 62.9 M | (3.6 K) | (2.5 M) | (14.5 M) | (25.3 M) | (25.5 M) | (24.2 M) |
| GOVX | (19.4 M) | (22.6 M) | (24.8 M) | (27.1 M) | (29.8 M) | (32.5 M) | (35.7 M) | (37.9 M) | (40.5 M) | (42.8 M) | (45.8 M) | (64.4 M) | (78.4 M) | (104.4 M) | (99.1 M) |
| NBY | (7.8 M) | (33.3 M) | (40.3 M) | (56.4 M) | (71.5 M) | (90.5 M) | (103.7 M) | (111.1 M) | (115 M) | (125 M) | (136.1 M) | (141.9 M) | (158.2 M) | (174.8 M) | (166.1 M) |
| SONN | (2 M) | (6 M) | (9.3 M) | (14.5 M) | (20.9 M) | (33 M) | (49.1 M) | (7.6 M) | (57.1 M) | (36.7 M) | (61.7 M) | (91.4 M) | (110.2 M) | (57.1 M) | (60 M) |
| PALI | (38.6 M) | (98.5 M) | (108.6 M) | (128.4 M) | (151.1 M) | (172 M) | (193 M) | (208.7 M) | (213.6 M) | (222 M) | (68 M) | (94.6 M) | (109.2 M) | (121.5 M) | (127.6 M) |
| DRUG | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (78.7 K) | (559.1 K) | (9.2 M) | (24.2 M) | (31.5 M) | (28.4 M) | (27 M) |
| VRAX | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4 M) | (4.6 M) | (6.3 M) | (11.8 M) | (18.5 M) | (17.6 M) |
| TNXP | (22.1 K) | (6.4 M) | (15.8 M) | (26.7 M) | (54.3 M) | (102.4 M) | (141.2 M) | (162.4 M) | (188.5 M) | (217.1 M) | (267.5 M) | (359.8 M) | (470 M) | (600.7 M) | (570.6 M) |
| ZURA | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (32.1 M) | (103.5 M) | (98.3 M) |
| CYTO | (13.6 M) | (13.6 M) | (18.2 M) | (33.1 M) | (52.1 M) | (81.6 M) | (112.3 M) | (136.1 M) | (146.3 M) | (152.8 M) | (160.6 M) | (176 M) | (201.4 M) | (18 M) | (18.9 M) |
| ENVB | (6.8 M) | (47.4 M) | (47.4 M) | (47.4 M) | (47.4 M) | (1.1 M) | (3.8 M) | (15 M) | (34.5 M) | (40.5 M) | (11.8 M) | (60.7 M) | (79.2 M) | (96.5 M) | (91.7 M) |
Xenetic Biosciences and related stocks such as Transcode Therapeutics, Landos Biopharma, and Neximmune Retained Earnings description
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.My Equities
My Current Equities and Potential Positions
| Xenetic Biosciences | XBIO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.11
Check out Xenetic Biosciences Performance and Xenetic Biosciences Correlation. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Xenetic Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.